Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lundbeck/Biotie Aim To Open Up Alcoholism Market By Trying To Reduce, Not Stop, Drinking

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

H. Lundbeck AS is planning to file for approval in Europe in the second half of 2011 for nalmefene – a drug touted as a novel and potentially revolutionary way of treating alcoholism – but currently is not planning to file in the U.S., presumably due to intellectual property issues.

You may also be interested in...



Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry

As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.

Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry

As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.

Alcoholism Drugs Wanted: Uncle Sam Offers Industry A Hand in R&D

As awareness of the biology of addiction slowly begins to take hold among the general population, medications could wind up being the next best thing to a Higher Power in helping to keep alcoholics sober

Topics

UsernamePublicRestriction

Register

PS004647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel